Journal Menu► ▼ Journal Menu
Journal Browser► ▼ Journal Browser
Special Issue "Marine Compounds in Neurodegenerative Diseases"
A special issue of Marine Drugs (ISSN 1660-3397).
Deadline for manuscript submissions: closed (24 August 2018).
Prof. Dr. Patrizia Russo Website E-Mail
1. IRCCS San Raffaele Pisana, Area of Clinical and Molecular Epidemiology, 00166 Rome, Italy
2. Department of Human Sciences and Quality of Life Promotion, San Raffaele University, Via di ValCannuta, 247, I-00166 Rome, Italy
Interests: Applied biology; neuronal and non-neuronal nicotinic receptor; COPD; addiction; Alzheimer’s disease; systems medicine; marine drugs in non communicable diseases
Prof. Dr. Massimo Fini E-Mail
Scientific Direction, IRCCS San Raffaele Pisana, Rome, Italy
Interests: Systems medicine, aging, frailty, rehabilitation, cardiovascular
Aging-associated neurodegenerative diseases (NDs), such as Alzheimer's disease (AD) and AD-like pathologies, such as changes in Aβ40/42 ratios, tau hyperphosphorylation and endosome abnormalities, Parkinson's disease (PD), frontotemporal degeneration (FTD) and amyotrophic lateral sclerosis (ALS), among others, are unremittingly progressive and fatal neurological diseases. NDs are characterized by irreversible loss of neurons/cholinergic or dopaminergic receptors functionality that results in apoptosis and, in turn, in severe atrophy of the affected patient brain regions. Pathogenesis of NDs are complex and the underlying mechanisms are yet to be fully explored.
Neurodegeneration is associated to neuroinflammation a dynamic biological response characterized by the recruitment of innate and adaptive immune system cells in the site of tissue damage. Activation of resident microglia and infiltrating immune cells may contribute to the disease process itself.
This Special Issue “Marine Compounds in Neurodegenerative Diseases” of Marine Drugs will cover the whole scope of agents targeting the mechanisms underlying NDs. This Special issue is focused on (but not limited to) compounds with relevant biological activities; however, preclinical drugs are also investigated.
Prof. Dr. Patrizia Russo
Prof. Dr. Massimo Fini
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Marine Drugs is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- neurodegenerative diseases
- marine compounds
- cell death
- cell survival
- drug resistance